EPAS1 and breast cancer: HIF2-α overexpressed breast cancer cells were then monitored for stem cell marker genes (c-Myc, Nanog, and OCT4) with and without PTX treatment, where there was an increase in the stemness genes and increased chemoresistance in cells with HIF2-α overexpression [145].